Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3CNS 1

Conditions

Breast Neoplasms 3Neoplasms by Site 1Neoplasms 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Breast Diseases 1Brain Neoplasms 1Brain Diseases 1

Interventions

pembrolizumab 610Carboplatin 375Paclitaxel 283Cisplatin 268Gemcitabine 256Pemetrexed 194Bevacizumab 191Nivolumab 190Docetaxel 190Injections 169Cyclophosphamide 148atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 129Fulvestrant 115durvalumab 114130-nm albumin-bound paclitaxel 111fludarabine 102Cetuximab 101Leucovorin 97Rituximab 96venetoclax 90Lenalidomide 84Prednisone 79enzalutamide 78Azacitidine 76Irinotecan 74Ipilimumab 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × RAD1901 × 1 year × Clear all
NCT05386108 2026-06-04

ELECTRA

Stemline Therapeutics, Inc.

Phase 1/2 Recruiting
73 enrolled
BreastCNS

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT05963997 2026-03-23

SUMIT-ELA

Carrick Therapeutics Limited

Phase 1/2 Completed
49 enrolled
Breast

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed
478 enrolled 16 charts 1 FDA
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡